Antibiotic Adjuvant 4-Hexylresorcinol Enhances the Efficiency of Antituberculosis Drugs.
Mycobacterium smegmatis
Mycobacterium tuberculosis
adjuvant 4-hexylresorcinol
isoniazid
rifabutin
Journal
Bulletin of experimental biology and medicine
ISSN: 1573-8221
Titre abrégé: Bull Exp Biol Med
Pays: United States
ID NLM: 0372557
Informations de publication
Date de publication:
15 Mar 2024
15 Mar 2024
Historique:
received:
24
05
2023
medline:
15
3
2024
pubmed:
15
3
2024
entrez:
15
3
2024
Statut:
aheadofprint
Résumé
We studied the possibility of using 4-hexylresorcinol to increase the efficiency of anti-mycobacterial chemotherapy. In an in vitro experiment, 4-hexylresorcinol increased the efficiency of rifampicin, kanamycin, and isoniazid against Mycobacterium smegmatis by 3-5 times. Experiments in sanitation of BALB/c mice infected with M. smegmatis showed the best efficacy of the isoniazid and 4-hexylresorcinol combination in comparison with isoniazid monotherapy. The growth-inhibiting activity of the combination of antibiotic rifabutin with 4-hexylresorcinol was shown on 6 strains of M. tuberculosis. A 2-fold decrease in the minimum inhibitory concentration of this antibiotic in the presence of half-minimum inhibitory concentration of 4-hexylresorcinol was demonstrated for monoresistant strain M. tuberculosis 5360/42H
Identifiants
pubmed: 38488964
doi: 10.1007/s10517-024-06048-5
pii: 10.1007/s10517-024-06048-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Springer Science+Business Media, LLC, part of Springer Nature.
Références
Jones F, Hu Y, Coates A. The efficacy of using combination therapy against multi-drug and extensively drug-resistant Pseudomonas aeruginosa in clinical settings. Antibiotics (Basel). 2022;11(3):323. doi: https://doi.org/10.3390/antibiotics11030323
doi: 10.3390/antibiotics11030323
pubmed: 35326786
pmcid: 8944682
González-Bello C. Antibiotic adjuvants — a strategy to unlock bacterial resistance to antibiotics. Bioorg. Med. Chem. Lett. 2017;27(18):4221-4228. doi: https://doi.org/10.1016/j.bmcl.2017.08.027
doi: 10.1016/j.bmcl.2017.08.027
pubmed: 28827113
Shemyakin IG, Manzenyuk OY, El’-Registan GI, Firstova VV, Kombarova TI, Gneusheva TY, Kyazimov EI, Nikolaev YA. Effect of 4-hexylresorcinol on the efficiency of antibiotic treatment of experimental sepsis caused by antibiotic-resistant Klebsiella pneumoniae strain in mice. Bull. Exp. Biol. Med. 2021;171(4):458-460. doi: https://doi.org/10.1007/s10517-021-05249-6
Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva, 2014.
Collins L, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents Chemother. 1997;41(5):1004-1009. doi: https://doi.org/10.1128/AAC.41.5.1004
doi: 10.1128/AAC.41.5.1004
pubmed: 9145860
pmcid: 163841
Biketov S, Potapov V, Ganina E, Downing K, Kana BD, Kaprelyants A. The role of resuscitation promoting factors in pathogenesis and reactivation of Mycobacterium tuberculosis during intra-peritoneal infection in mice. BMC Infect. Dis. 2007;7:146. doi: https://doi.org/10.1186/1471-2334-7-146
doi: 10.1186/1471-2334-7-146
pubmed: 18086300
pmcid: 2241625
Manzenyuk OYu, Nikolaev YuA, Mukhina TN, Firstova VV, Kyazimov EI, Shemyakin IG. Comparative evaluation of the antibacterial effectiveness of rifabutin and a combination of rifabutin with 4-hexylresorcin against antibiotic-resistant Mycobacterium tuberculosis in vitro. Bakteriologiya. 2022;7(4):66-68. Russian. doi: https://doi.org/10.20953/2500-1027-2022-4-66-68
Nikolaev YA, Tutel’yan AV, Loiko NG, Buck J, Sidorenko SV, Lazareva I, Gostev V, Manzen’yuk OY, Shemyakin IG, Abramovich RA, Huwyler J, El’-Registan GI. The use of 4-Hexylresorcinol as antibiotic adjuvant. PLoS One. 2020;15(9):e0239147. doi: https://doi.org/10.1371/journal.pone.0239147
Koshechkin VA, Ivanova ZA. Tuberculosis. Moscow, 2007. P. 194. Russian.